Navigation Links
AEterna Zentaris completes management team with the appointment of Chief Medical Officer
Date:8/19/2007

shed a world class team," said Dr. Mazzo. "I believe that with this experienced, highly competent team along with our rich, self-sustaining pipeline, we have all the key elements to successfully place AEterna Zentaris in a new growth category and significantly unlock shareholder value."

Following Dr. Blake's appointment, the Company's Executive Management Team is comprised of the following members:

- Paul Blake, M.D., Senior Vice President and Chief Medical Officer;

- Jurgen Engel, Ph.D., Executive Vice President and Chief Scientific

Officer;

- Ellen McDonald, M.B.A., Senior Vice President, Business Operations and

Chief Business Officer;

- Mario Paradis, C.A., Senior Vice President, Administrative and Legal

Affairs, and Corporate Secretary;

- Nicholas J. Pelliccione, Ph.D., Senior Vice President, Regulatory

Affairs and Quality Assurance; and

- Dennis Turpin, C.A., Senior Vice President and Chief Financial Officer.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and
'/>"/>

SOURCE AETERNA ZENTARIS INC.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... a multi-arm Phase 1 study of MM-141, a bispecific ... in an oral session by Dr. Mansoor Saleh ... Research Annual Meeting in Philadelphia, PA. ... MM-141 as a monotherapy and in combination with everolimus ...
(Date:4/21/2015)... , April 21, 2015 Invetech ... development, custom automation, and contract manufacturing, and  NanoCellect ... flow cytometry and cell sorting technology for life ... a novel flow cytometry platform. Headquartered ... Biomedical has developed a microchip-based cell sorting technology. ...
(Date:4/21/2015)... 21, 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: ... call on Thursday, April 23, 4:30 p.m. ET. Participants ... follows: Investor call information: ... International toll number: (925) 418-7845 Participant Passcode: 32888538 ... Tina Amirkiai , tina.amirkiai@fleishman.com . Access ...
(Date:4/21/2015)... YORK , April 21, 2015 Immune ... that its Board of Directors has elected Rene-Pierre ... the Transaction and Pricing Committee, with oversight on strategic ... member of the Audit Committee, the Compensation Committee and ... his election, Mr. Azria commented: "I have a long-time ...
Breaking Biology Technology:First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4
... Alzheimer,s Association® in conjunction with GE Healthcare held ... discussion during the Alzheimer,s Association International Conference 2011 ... Alzheimer,s field and revealed new data from a ... impact of Alzheimer,s disease on women and highlighted ...
... Biocept, Inc. announced today that it has appointed ... Chief Financial Officer.  As CFO, Mr. Kachioff will be ... investor relations, risk management and information systems functions. Kachioff ... helping to build life science companies. Prior to joining ...
... response to the H1N1 flu virus, could help to ease ... been infected with the flu virus. In a ... Journal of Breath Research , researchers have investigated an easy, ... to the H1N1 strain. Research published last month ...
Cached Biology Technology:Women at the Center of the Global Alzheimer's Epidemic 2Women at the Center of the Global Alzheimer's Epidemic 3Women at the Center of the Global Alzheimer's Epidemic 4Biocept, Inc. Announces New CFO 2Biocept, Inc. Announces New CFO 3'Swine flu' breath test could reduce future vaccination shortages, research suggests 2
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... The critical enzyme beta-secretase1 (BACE1) is known to be elevated ... found increased levels of BACE1 in brains with mild cognitive ... of mild cognitive impairment to AD and may be an ... January issue of The American Journal of Pathology . ...
... Utah Health Sciences faculty members whose research has ... inventions, and startup companies have been named fellows ... Carl W. Wittwer, M.D., Ph.D., professor of pathology ... Ph.D., professor of internal medicine and chief of ...
... soft and it won,t pump blood, but too hard and it ... of strain that a beating heart can generate and still beat ... published in the journal Current Biology , researchers at the ... the stiffness of the collagen framework that the heart,s cells live ...
Cached Biology News:Enzyme BACE1 may be important in predicting onset of Alzheimer disease 2Researchers named to National Academy of Inventors 2Researchers named to National Academy of Inventors 3Researchers named to National Academy of Inventors 4Researchers at Penn show optimal framework for heartbeats 2Researchers at Penn show optimal framework for heartbeats 3
G-protein coupled purinergic receptor P2Y8...
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Biology Products: